Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

Approximately 40% of participants did not seroconvert or achieve a conservative neutralization threshold post-vaccination.

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of RSV ...

“Dr. Chen Chih-jung of Linkou Chang Gung Memorial Hospital stated in an interview on Thursday that hMPV is similar to ...

Flu, Respiratory Syncytial Virus (RSV) and COVID-19 cases are on the rise in East Texas mostly impacting children. The Texas ...

More Americans believe in the effectiveness of vaccines developed to protect newborns and seniors against respiratory ...

Zelpultide alfa is under clinical development by Airway Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...

The U.S. Centers for Disease Control and Prevention said on Thursday its analysis of samples from the first severe case of ...

A genetic analysis of viral samples from a patient in Louisiana hospitalized with the first severe case of bird flu showed ...